Dose-response Study of Exendin-9,39 on Glucose Metabolism
NCT ID: NCT01218633
Last Updated: 2013-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
11 participants
INTERVENTIONAL
2011-05-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism
NCT00571324
Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans
NCT00393445
Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
NCT00835328
Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity
NCT00897676
The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes
NCT01181986
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Saline
saline infusion
saline infused at 30ml/hour
GLP-1-(9,36)-amide
GLP-1-9,36 infusion
infused @ 1.2pmol/kg/min
Exendin-9,39 @30pmol/kg/min
Exendin-9,39 at low dose
infused at 30pmol/kg/min
Exendin-9,39 @300pmol/kg/min
Exendin-9,39 at high dose
infused @ 300pmol/kg/min
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
saline infusion
saline infused at 30ml/hour
GLP-1-9,36 infusion
infused @ 1.2pmol/kg/min
Exendin-9,39 at low dose
infused at 30pmol/kg/min
Exendin-9,39 at high dose
infused @ 300pmol/kg/min
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
20 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Adrian Vella
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adrian Vella
Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adrian Vella, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sathananthan M, Farrugia LP, Miles JM, Piccinini F, Dalla Man C, Zinsmeister AR, Cobelli C, Rizza RA, Vella A. Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, beta-cell function, and glucose metabolism in nondiabetic subjects. Diabetes. 2013 Aug;62(8):2752-6. doi: 10.2337/db13-0140. Epub 2013 Apr 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-003435
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.